Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Tilmicosin
Elanco Animal Health, Eli Lilly and Company Limited
QJ01FA91
Tilmicosin
250 milligram(s)/millilitre
Oral solution
POM: Prescription Only Medicine as defined in relevant national legislation
Fowl - Chicken, Fowl - Turkey, Porcine
tilmicosin
Antibacterial
Authorised
1999-02-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Pulmotil AC Concentrate for oral solution for use in drinking water or milk replacer 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Tilmicosin (as phosphate) 250 mg/ml EXCIPIENTS: Propyl gallate Disodium edetate For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for Oral Solution for use in drinking water or milk replacer. Clear yellow to amber coloured solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Chickens (except hens producing eggs for human consumption) Turkeys Pigs Calves (non ruminant) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Pigs: For the treatment and prevention of respiratory disease in pig herds, associated with_ Mycoplasma hyopneumoniae,_ _Pasteurella multocida, Actinobacillus pleuropneumoniae_ and other organisms susceptible to tilmicosin. Chickens: For the treatment and prevention of respiratory disease in chicken flocks, associated with_ Mycoplasma_ _gallisepticum_ and_ M. synoviae._ Turkeys: For the treatment and prevention of respiratory disease in turkey flocks, associated with_ Mycoplasma_ _gallisepticum_ and_ M. synoviae._ Calves: For the treatment and prevention of bovine respiratory disease, associated with_ Mannheimia haemolytica,_ _Pasteurella multocida, Mycoplasma bovis, M. dispar_ and other organisms susceptible to tilmicosin. 4.3 CONTRAINDICATIONS Do not allow horses and other equines access to drinking water containing tilmicosin. Do not use in case of hypersensitivity to tilmicosin or to any of the excipients. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Read the complete document